Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 1;173(7):787-96.
doi: 10.1093/aje/kwq438. Epub 2011 Mar 2.

Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes

Jennifer L St Sauver  1 , Debra J Jacobson, Michaela E McGree, Cynthia J Girman, George G Klee, Michael M Lieber, Steven J Jacobsen
Affiliations

Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes

Jennifer L St Sauver et al. Am J Epidemiol. .

Abstract

Some men have rapid increases in benign prostatic enlargement and lower urinary tract symptoms (LUTS), and it is not clear how sex steroid hormones contribute to the rates of change in these urologic outcomes. Therefore, the authors conducted a population-based cohort study of 648 men residing in Olmsted County, Minnesota, from 1990 to 2007, to examine associations between baseline sex steroid hormones, the rate of change in these hormones, and the rates of change in LUTS, maximum urinary flow rate, and prostate volume. Annual changes in hormone levels and urologic outcomes were calculated using mixed-effects regression models. Associations between hormone variables and rates of change in urologic outcomes were assessed with linear regression models. Higher baseline estradiol levels and rapid declines in estradiol over time were associated with rapid increases in LUTS and rapid decreases in maximum flow rate. Lower baseline bioavailable testosterone levels and more rapid declines in bioavailable testosterone were associated with more rapid increases in prostate volume. These results suggest that both absolute sex steroid hormone levels and the rates at which the levels change may be important in the development of urologic conditions in aging men.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participation, dropout, and loss to follow-up during each round of the cohort study, Olmsted County, Minnesota, 1990–2007.
Figure 2.
Figure 2.
A) Natural log-transformed testosterone levels by age at the time of the measurement (rounds 2 through 9), Olmsted County, Minnesota, 1990–2007. B) Natural log-transformed testosterone levels by age at the time of the measurement (rounds 2 through 9) with all measures standardized to round 9 hormone levels.
Figure 3.
Figure 3.
A) Mean baseline hormone values by baseline age group, Olmsted County, Minnesota, 1990–2007. The closed diamonds indicate testosterone (ng/dL), the open circles indicate estradiol (pg/mL), and the X's indicate bioavailable testosterone (ng/dL). B) Mean annual changes in hormones by baseline age group. The closed diamonds indicate testosterone, the open circles indicate estradiol, and the X's indicate bioavailable testosterone.
See this image and copyright information in PMC

References

    1. Griffiths K. Molecular control of prostate growth. In: Kirby R, McConnell JD, Fitzpatrick J, et al., editors. Textbook of Benign Prostatic Hyperplasia. Oxford, United Kingdom: Isis Medical Media Ltd; 1996. pp. 23–56.
    1. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev. 1992;14(1):131–153. - PubMed
    1. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008;72(2):247–254. - PMC - PubMed
    1. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398. - PubMed
    1. Kaplan SA, Roehrborn CG, McConnell JD, et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol. 2008;180(3):1030–1032. - PubMed

Publication types

MeSH terms